MX2022008727A - Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca. - Google Patents
Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca.Info
- Publication number
- MX2022008727A MX2022008727A MX2022008727A MX2022008727A MX2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- hypertrophy
- heart failure
- myeloid
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008727A true MX2022008727A (es) | 2022-10-07 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008727A MX2022008727A (es) | 2020-01-21 | 2021-01-19 | Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11980654B2 (en) | 2020-09-22 | 2024-05-14 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| JP2024501821A (ja) | 2020-12-23 | 2024-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓組織細胞に対する特異性を有するウイルスカプシドタンパク質 |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| CA3258215A1 (en) | 2022-06-03 | 2023-12-07 | Boehringer Ingelheim International Gmbh | RECOMBINANT EXPRESSION OF THE MYELOID-DERIVED GROWTH FACTOR |
| CN120112304A (zh) | 2022-09-08 | 2025-06-06 | 勃林格殷格翰国际有限公司 | 用于治疗心源性休克的髓源性生长因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| WO2025120204A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| WO1997047358A1 (en) | 1996-06-11 | 1997-12-18 | Merck & Co., Inc. | Synthetic hepatitis c genes |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| AU4220797A (en) * | 1996-09-13 | 1998-04-02 | Protegene Inc. | Human proteins having secretory signal sequences and DNAs encoding these prot eins |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| EP3747457A3 (en) | 2013-01-17 | 2021-03-03 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| KR20250133994A (ko) * | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023511358A (ja) | 2023-03-17 |
| TW202142254A (zh) | 2021-11-16 |
| EP4093750A1 (en) | 2022-11-30 |
| CA3164500A1 (en) | 2021-07-29 |
| WO2021148411A1 (en) | 2021-07-29 |
| JP7777532B2 (ja) | 2025-11-28 |
| BR112022014272A2 (pt) | 2022-09-20 |
| AU2021211874A1 (en) | 2022-08-25 |
| CA3223879A1 (en) | 2021-07-29 |
| CN115698048A (zh) | 2023-02-03 |
| PH12022551792A1 (en) | 2023-09-18 |
| KR20220131262A (ko) | 2022-09-27 |
| US20230059560A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551792A1 (en) | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure | |
| MX2022005236A (es) | Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina. | |
| PH12020551957A1 (en) | Codon-optimized acid alpha-glucosidase expression cassettes and methods of using same | |
| MX2016005101A (es) | Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso. | |
| MX2020006424A (es) | Polipéptidos de dominio de unión a células de toxina botulínica y métodos de uso para el rejuvenecimiento de la piel. | |
| WO2016172156A3 (en) | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose | |
| ATE352626T1 (de) | Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren | |
| WO2016172153A3 (en) | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose | |
| NZ595497A (en) | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them | |
| DK1513937T3 (da) | Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved | |
| DK1474507T3 (da) | Fremgangsmåder og materialer til produktion af organiske produkter i celler af Candida arter | |
| MX2020005724A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| ATE450603T1 (de) | Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren | |
| FR2862312B1 (fr) | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas | |
| DE60036537D1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
| WO2022235933A3 (en) | Compositions and methods for treating sensorineural hearing loss using stereocilin dual vector systems | |
| SA523451188B1 (ar) | شظية ربط مولد الضد مضادة لـليمفوبويتين الغدة الصعترية ذو ثبات محسن | |
| WO2010002160A3 (ko) | 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 | |
| MX2017013174A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos. | |
| ATE377649T1 (de) | Verfahren und zelle zur expression von rekombinanten proteinprodukten | |
| MX2025002493A (es) | Factor de crecimiento derivado de mieloides para su uso en el tratamiento del shock cardiogenico | |
| DOP2025000239A (es) | Compuestos y métodos para reducir la expresión de pln | |
| MX2017013088A (es) | Metodos novedosos para el control de la aflatoxina y de infecciones fungicas. | |
| WO2022026950A3 (en) | Cst6, cells expressing cst6 and methods of use | |
| WO2017062666A3 (en) | Enzyme replacement therapy for mucopolysaccharidosis iiid |